US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US5336603A
(en)
*
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
US5750375A
(en)
*
|
1988-01-22 |
1998-05-12 |
Zymogenetics, Inc. |
Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
|
US5567584A
(en)
*
|
1988-01-22 |
1996-10-22 |
Zymogenetics, Inc. |
Methods of using biologically active dimerized polypeptide fusions to detect PDGF
|
US6018026A
(en)
|
1988-01-22 |
2000-01-25 |
Zymogenetics, Inc. |
Biologically active dimerized and multimerized polypeptide fusions
|
US6685941B1
(en)
|
1988-11-23 |
2004-02-03 |
The Regents Of The University Of Michigan |
Methods of treating autoimmune disease via CTLA-4Ig
|
US5225538A
(en)
*
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5242687A
(en)
*
|
1989-03-15 |
1993-09-07 |
Tkb Associates Limited Partnership |
Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
|
ES2238070T3
(es)
*
|
1989-04-21 |
2005-08-16 |
Amgen Inc. |
Receptor del tnf, proteina ligante del tnf y adn codante para estos.
|
US7264944B1
(en)
|
1989-04-21 |
2007-09-04 |
Amgen Inc. |
TNF receptors, TNF binding proteins and DNAs coding for them
|
IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
US6143866A
(en)
*
|
1989-07-18 |
2000-11-07 |
Amgen, Inc. |
Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
|
US6267964B1
(en)
*
|
1989-08-01 |
2001-07-31 |
Affibody Technology Sweden Ab |
Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
|
NZ235148A
(en)
|
1989-09-05 |
1991-12-23 |
Immunex Corp |
Tumour necrosis factor receptor protein and dna sequences
|
US6541610B1
(en)
|
1989-09-05 |
2003-04-01 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
US5395760A
(en)
*
|
1989-09-05 |
1995-03-07 |
Immunex Corporation |
DNA encoding tumor necrosis factor-α and -β receptors
|
US5605690A
(en)
*
|
1989-09-05 |
1997-02-25 |
Immunex Corporation |
Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
|
US5945397A
(en)
*
|
1989-09-05 |
1999-08-31 |
Immunex Corporation |
Purified p75 (type II) tumor necrosis factor receptor polypeptides
|
DE10399023I2
(de)
*
|
1989-09-12 |
2006-11-23 |
Ahp Mfg B V |
TFN-bindende Proteine
|
US5216132A
(en)
*
|
1990-01-12 |
1993-06-01 |
Protein Design Labs, Inc. |
Soluble t-cell antigen receptor chimeric antigens
|
US6552170B1
(en)
*
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
GB9022543D0
(en)
*
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
DE4037837A1
(de)
*
|
1990-11-28 |
1992-06-04 |
Behringwerke Ag |
Zellfreie rezeptorbindungsteste, ihre herstellung und verwendung
|
US7070991B2
(en)
*
|
1991-02-08 |
2006-07-04 |
Progenics Pharmaceuticals, Inc. |
Cells expressing a CD4-IgG2 chimeric heterotetramer
|
JP3670276B2
(ja)
|
1991-02-08 |
2005-07-13 |
プロゲニクス・ファーマスーティカルズ、インコーポレイテッド |
CD4― ガンマ・2キメラ及びCD4 ― IgG2・キメラ
|
ATE193724T1
(de)
*
|
1991-03-12 |
2000-06-15 |
Biogen Inc |
Cd2 bindender bereich für das lymphocyten- funktion assoziierte antigen-3
|
MX9203138A
(es)
*
|
1991-03-12 |
1992-09-01 |
Biogen Inc |
Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
|
US6582959B2
(en)
*
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
US20030206899A1
(en)
*
|
1991-03-29 |
2003-11-06 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
US5318890A
(en)
*
|
1991-05-06 |
1994-06-07 |
The Regents Of The University Of California |
Assays for inhibitors of leukocyte adhesion
|
US6797492B2
(en)
|
1991-05-17 |
2004-09-28 |
Merck & Co., Inc. |
Method for reducing the immunogenicity of antibody variable domains
|
US5851795A
(en)
*
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
US5844095A
(en)
*
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
EP0533006A1
(de)
*
|
1991-09-18 |
1993-03-24 |
F.Hoffmann-La Roche & Co. Aktiengesellschaft |
Chimäre Interleukin 5-Rezeptor/Immunoglobulin-Polypeptide
|
US6764681B2
(en)
*
|
1991-10-07 |
2004-07-20 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
US5871734A
(en)
*
|
1992-01-13 |
1999-02-16 |
Biogen, Inc. |
Treatment for asthma with VLA-4 blocking agents
|
US6399368B1
(en)
|
1992-01-17 |
2002-06-04 |
Board Of Regents, The University Of Texas System |
Secretion of T cell receptor fragments from recombinant Escherichia coli cells
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US5932214A
(en)
*
|
1994-08-11 |
1999-08-03 |
Biogen, Inc. |
Treatment for inflammatory bowel disease with VLA-4 blockers
|
CA2133326C
(en)
*
|
1992-03-30 |
2005-03-01 |
Craig A. Smith |
Fusion proteins comprising tumor necrosis factor receptor
|
CA2118508A1
(en)
*
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
US5540926A
(en)
*
|
1992-09-04 |
1996-07-30 |
Bristol-Myers Squibb Company |
Soluble and its use in B cell stimulation
|
WO1994005314A1
(en)
*
|
1992-09-08 |
1994-03-17 |
Centocor, Inc. |
Peptide inhibitors of leukocyte adhesion
|
WO1994006476A1
(en)
*
|
1992-09-15 |
1994-03-31 |
Immunex Corporation |
Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
|
DE69310525T2
(de)
*
|
1992-09-16 |
1997-10-02 |
Genentech Inc |
Schutz gegen leberschäden mit hgf
|
WO1994006469A1
(en)
*
|
1992-09-18 |
1994-03-31 |
La Jolla Institute For Allergy And Immunology |
Hiv fusion polypeptide
|
US6270766B1
(en)
|
1992-10-08 |
2001-08-07 |
The Kennedy Institute Of Rheumatology |
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
|
US5474766A
(en)
*
|
1992-12-18 |
1995-12-12 |
Washington University |
Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator
|
WO1994014836A1
(en)
*
|
1992-12-18 |
1994-07-07 |
Centocor, Inc. |
Peptide inhibitors of selectin binding
|
ATE174344T1
(de)
*
|
1993-01-25 |
1998-12-15 |
Dana Farber Cancer Inst Inc |
Chimäre selektine erhältlich durch domänenaustauch und ihre verwendungen
|
US7534867B1
(en)
|
1993-05-19 |
2009-05-19 |
Schering Corporation |
Purified mammalian Flt3 ligands; agonists; antagonists
|
US6723705B1
(en)
|
1993-08-19 |
2004-04-20 |
Gentics Institute, Inc. |
Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
|
US20050129670A1
(en)
*
|
1993-07-26 |
2005-06-16 |
Genetics Institute, Llc. |
Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
|
US6084067A
(en)
*
|
1993-07-26 |
2000-07-04 |
Dana-Farber Cancer Institute |
CTLA4/CD28 ligands and uses therefor
|
US6130316A
(en)
*
|
1993-07-26 |
2000-10-10 |
Dana Farber Cancer Institute |
Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
|
US5861310A
(en)
*
|
1993-11-03 |
1999-01-19 |
Dana-Farber Cancer Institute |
Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
|
US6824779B1
(en)
|
1993-07-26 |
2004-11-30 |
Dana-Farber Cancer Institute, Inc. |
Methods for inhibiting the interaction of B7-2 with its natural ligand
|
SE9302855D0
(sv)
*
|
1993-09-06 |
1993-09-06 |
Martin Lindberg |
Method and means for producing plasmaproteinase inhibitor binding proteins
|
WO1995014787A1
(en)
*
|
1993-11-22 |
1995-06-01 |
Centocor, Inc. |
Peptide inhibitors of selecting binding
|
EP0742830B1
(de)
*
|
1994-02-01 |
2001-07-18 |
THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services |
Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten
|
US7294331B2
(en)
*
|
1994-03-07 |
2007-11-13 |
Immunex Corporation |
Methods of using flt3-ligand in hematopoietic cell transplantation
|
WO1995024217A1
(en)
|
1994-03-08 |
1995-09-14 |
Dana-Farber Cancer Institute |
Methods for modulating t cell unresponsiveness
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
IL113484A0
(en)
*
|
1994-04-28 |
1995-07-31 |
Immunex Corp |
Viral proteins pharmaceutical compositions containing them their preparation and use
|
CN1110557C
(zh)
|
1994-05-06 |
2003-06-04 |
古斯达威罗斯研究所 |
Lag-3蛋白的可溶性多肽组分;生产方法、治疗组合物、抗独特型抗体
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US6309853B1
(en)
|
1994-08-17 |
2001-10-30 |
The Rockfeller University |
Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
|
US6429290B1
(en)
|
1994-08-17 |
2002-08-06 |
The Rockefeller University |
OB polypeptides, modified forms and derivatives
|
US6048837A
(en)
*
|
1994-08-17 |
2000-04-11 |
The Rockefeller University |
OB polypeptides as modulators of body weight
|
US6124448A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockfeller University |
Nucleic acid primers and probes for the mammalian OB gene
|
US6471956B1
(en)
|
1994-08-17 |
2002-10-29 |
The Rockefeller University |
Ob polypeptides, modified forms and compositions thereto
|
US6350730B1
(en)
|
1994-08-17 |
2002-02-26 |
The Rockefeller University |
OB polypeptides and modified forms as modulators of body weight
|
US5541087A
(en)
*
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
US5814464A
(en)
*
|
1994-10-07 |
1998-09-29 |
Regeneron Pharma |
Nucleic acids encoding TIE-2 ligand-2
|
WO1996018412A1
(en)
*
|
1994-12-12 |
1996-06-20 |
Beth Israel Hospital Association |
Chimeric cytokines and uses thereof
|
US6410008B1
(en)
*
|
1994-12-12 |
2002-06-25 |
Beth Israel Hospital Association |
Chimeric IL-10 proteins and uses thereof
|
US6808709B1
(en)
*
|
1994-12-30 |
2004-10-26 |
The Regents Of The University Of California |
Immunoglobulins containing protection proteins and their use
|
US6485726B1
(en)
*
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US6086875A
(en)
*
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
US6030613A
(en)
*
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US20030069196A1
(en)
*
|
1995-03-03 |
2003-04-10 |
Millennium Pharmaceuticals, Inc. |
Compositions and methods for the treatment and diagnosis of immune disorders
|
US6066322A
(en)
|
1995-03-03 |
2000-05-23 |
Millennium Pharmaceuticals, Inc. |
Methods for the treatment of immune disorders
|
US6455685B1
(en)
|
1995-03-03 |
2002-09-24 |
Millennium Pharmaceuticals, Inc. |
Compositions and methods for the treatment and diagnosis of immune disorders
|
US6211142B1
(en)
*
|
1995-03-10 |
2001-04-03 |
Genentech, Inc. |
Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
|
NZ306653A
(en)
*
|
1995-03-23 |
1999-03-29 |
Immunex Corp |
Isolated dna il-17 receptors
|
US6680057B1
(en)
*
|
1995-03-23 |
2004-01-20 |
Immunex Corporation |
Methods of treating autoimmune disease by administering interleukin-17 receptor
|
US20060193862A1
(en)
*
|
1995-03-30 |
2006-08-31 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
IL117645A
(en)
*
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
US6113898A
(en)
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
US7175847B1
(en)
*
|
1995-06-07 |
2007-02-13 |
Biogen Idec Inc. |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
|
US7153508B2
(en)
*
|
1995-06-07 |
2006-12-26 |
Biogen Idec Inc. |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
|
US7150992B1
(en)
|
1995-10-04 |
2006-12-19 |
Innunex Corporation |
Methods of preparing dendritic cells with flt3-ligand and antigen
|
US7361330B2
(en)
*
|
1995-10-04 |
2008-04-22 |
Immunex Corporation |
Methods of using flt3-ligand in the treatment of fibrosarcoma
|
US20020034517A1
(en)
*
|
1995-10-04 |
2002-03-21 |
Kenneth Brasel |
Dendritic cell stimulatory factor
|
US6936439B2
(en)
*
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
US20030040467A1
(en)
*
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
US20030026779A1
(en)
*
|
1999-10-15 |
2003-02-06 |
Liming Yu |
Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc
|
GB9526733D0
(en)
*
|
1995-12-30 |
1996-02-28 |
Delta Biotechnology Ltd |
Fusion proteins
|
EP0885299B1
(de)
|
1996-01-08 |
2005-10-26 |
Genentech, Inc. |
Ob-rezeptor und liganden
|
US6750334B1
(en)
*
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
US5917026A
(en)
*
|
1996-02-05 |
1999-06-29 |
Loewenadler; Bjoern |
Fusion proteins of immunopotentiating activity
|
NZ503548A
(en)
|
1996-02-09 |
2001-09-28 |
Amgen Inc |
A fusion protein comprising an IL-1ra receptor antagonist with a constant domain of human immunoglobulin at the carboxy terminus
|
US6194177B1
(en)
*
|
1996-02-20 |
2001-02-27 |
Applied Research Systems Ars Holding N.V. |
DNA encoding a hybrid heterodimeric protein
|
JP4140927B2
(ja)
*
|
1996-02-20 |
2008-08-27 |
アプライド リサーチ システムズ アース ホールディング エヌ.ヴィ. |
ヘテロ二量体を形成するハイブリッドタンパク質
|
GB9604518D0
(en)
*
|
1996-03-02 |
1996-05-01 |
Smithkline Beecham Plc |
Novel compounds
|
US6458354B1
(en)
|
1996-03-28 |
2002-10-01 |
The Johns Hopkins University |
Molecular complexes which modify immune responses
|
CA2250166A1
(en)
*
|
1996-03-28 |
1997-10-02 |
The Johns Hopkins University |
Soluble divalent and multivalent heterodimeric analogs of proteins
|
US6140305A
(en)
*
|
1996-04-04 |
2000-10-31 |
Bio-Rad Laboratories, Inc. |
Hereditary hemochromatosis gene products
|
US7026116B1
(en)
*
|
1996-04-04 |
2006-04-11 |
Bio-Rad Laboratories, Inc. |
Polymorphisms in the region of the human hemochromatosis gene
|
US7063965B2
(en)
*
|
1996-04-05 |
2006-06-20 |
Regeneron Pharmaceuticals, Inc. |
Nucleic acid encoding TIE-2 ligand
|
US6060054A
(en)
*
|
1996-04-10 |
2000-05-09 |
National Jewish Medical And Research Center |
Product for T lymphocyte immunosuppression
|
US6117977A
(en)
*
|
1996-04-24 |
2000-09-12 |
Genentech, Inc. |
Type C lectins
|
ES2243995T3
(es)
*
|
1996-04-26 |
2005-12-01 |
Beth Israel Deaconess Medical Center, Inc. |
Antagonistas de interleucina-15.
|
US6451308B1
(en)
*
|
1996-04-26 |
2002-09-17 |
Beth Israel Deaconess Medical Center |
Antagonists of interleukin-15
|
CA2253494A1
(en)
*
|
1996-05-02 |
1997-11-13 |
Mochida Pharmaceutical Co., Ltd. |
Novel fas antigen derivative
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
US6849399B1
(en)
|
1996-05-23 |
2005-02-01 |
Bio-Rad Laboratories, Inc. |
Methods and compositions for diagnosis and treatment of iron misregulation diseases
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
JP4382879B2
(ja)
*
|
1996-07-12 |
2009-12-16 |
ジェネンテック・インコーポレーテッド |
ガンマ―ヘレグリン
|
JP4274581B2
(ja)
*
|
1996-07-12 |
2009-06-10 |
ジェネンテック・インコーポレーテッド |
キメラヘテロ多量体接着体
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
CA2273852C
(en)
|
1996-12-06 |
2009-09-29 |
Amgen Inc. |
Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
|
DE69724451T2
(de)
|
1996-12-06 |
2004-03-18 |
Amgen Inc., Thousand Oaks |
Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
|
US20030171551A1
(en)
*
|
1997-01-31 |
2003-09-11 |
Joseph D. Rosenblatt |
Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
|
US6268411B1
(en)
|
1997-09-11 |
2001-07-31 |
The Johns Hopkins University |
Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
|
US7435793B2
(en)
*
|
1998-05-15 |
2008-10-14 |
Genentech, Inc. |
Peptides that induce chondrocyte redifferentiation
|
US20020137890A1
(en)
*
|
1997-03-31 |
2002-09-26 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
DE69837085T3
(de)
|
1997-04-16 |
2012-01-12 |
Millennium Pharmaceuticals, Inc. |
Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen
|
US6190909B1
(en)
*
|
1997-04-17 |
2001-02-20 |
Millennium Pharmaceuticals, Inc. |
TH2-specific gene
|
WO1998049305A1
(en)
*
|
1997-05-01 |
1998-11-05 |
Amgen Inc. |
Chimeric opg polypeptides
|
US20020062010A1
(en)
*
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
US7951917B1
(en)
*
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
CA2288600C
(en)
|
1997-05-02 |
2010-06-01 |
Genentech, Inc. |
A method for making multispecific antibodies having heteromultimeric and common components
|
US20030207346A1
(en)
*
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
AU745403B2
(en)
|
1997-06-13 |
2002-03-21 |
Bio-Rad Laboratories, Inc. |
Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
|
US20020132252A1
(en)
*
|
1997-06-16 |
2002-09-19 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20040191256A1
(en)
*
|
1997-06-24 |
2004-09-30 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
KR100220645B1
(ko)
*
|
1997-07-04 |
1999-09-15 |
구광시 |
벤젠유도체의 제조방법
|
US6187564B1
(en)
|
1997-07-10 |
2001-02-13 |
Beth Israel Deaconess Medical Center |
DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
|
US6242570B1
(en)
|
1997-07-10 |
2001-06-05 |
Beth Israel Deaconess Medical Center |
Production and use of recombinant protein multimers with increased biological activity
|
US6165476A
(en)
*
|
1997-07-10 |
2000-12-26 |
Beth Israel Deaconess Medical Center |
Fusion proteins with an immunoglobulin hinge region linker
|
US20030170794A1
(en)
*
|
1997-09-18 |
2003-09-11 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6391311B1
(en)
*
|
1998-03-17 |
2002-05-21 |
Genentech, Inc. |
Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
|
US6689607B2
(en)
|
1997-10-21 |
2004-02-10 |
Human Genome Sciences, Inc. |
Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
|
US6509173B1
(en)
*
|
1997-10-21 |
2003-01-21 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
|
US6503184B1
(en)
|
1997-10-21 |
2003-01-07 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
|
US20040136986A1
(en)
*
|
1997-10-31 |
2004-07-15 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
US6576743B1
(en)
*
|
1997-11-26 |
2003-06-10 |
Zymogenetics, Inc. |
Mammalian cytokine-like polypeptide-10
|
CA2312188C
(en)
|
1997-12-08 |
2010-06-29 |
Lexigen Pharmaceuticals Corp. |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
US6207413B1
(en)
*
|
1998-01-22 |
2001-03-27 |
Regeneron Pharmaceuticals, Inc. |
Nucleic acids encoding novel orphan cytokine receptors
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
US7198789B2
(en)
*
|
1998-03-17 |
2007-04-03 |
Genetics Institute, Llc |
Methods and compositions for modulating interleukin-21 receptor activity
|
US7189400B2
(en)
*
|
1998-03-17 |
2007-03-13 |
Genetics Institute, Llc |
Methods of treatment with antagonists of MU-1
|
US6057128A
(en)
|
1998-03-17 |
2000-05-02 |
Genetics Institute, Inc. |
MU-1, member of the cytokine receptor family
|
US7371836B2
(en)
*
|
1998-03-27 |
2008-05-13 |
Genentech, Inc. |
PRO526 nucleic acids
|
US7723488B2
(en)
*
|
1998-03-27 |
2010-05-25 |
Genentech, Inc. |
Monoclonal antibodies to secreted and transmembrane polypeptides
|
BR9909583A
(pt)
*
|
1998-04-15 |
2002-01-15 |
Lexigen Pharm Corp |
Aumento da resposta imune mediado por uma proteìna de fusão anticorpo-citocina por co-administração com inibidor de angiogênese
|
US20020192751A1
(en)
*
|
1998-05-15 |
2002-12-19 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
DE69936382T3
(de)
*
|
1998-05-15 |
2011-07-07 |
Genentech, Inc., Calif. |
Therapeutische verwendungen von il-17 homologe polypeptide
|
AU4561199A
(en)
|
1998-06-12 |
1999-12-30 |
Genentech Inc. |
Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
|
US20050181482A1
(en)
*
|
2004-02-12 |
2005-08-18 |
Meade Harry M. |
Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
|
US6548653B1
(en)
*
|
1998-06-15 |
2003-04-15 |
Genzyme Transgenics Corporation |
Erythropoietin analog-human serum albumin fusion
|
US20030065154A1
(en)
*
|
2000-03-30 |
2003-04-03 |
Genentech, Inc. |
Interleukin-8 homologous polypeptides and therapeutic uses thereof
|
US20070003545A9
(en)
*
|
1999-06-02 |
2007-01-04 |
Eaton Dan L |
Interleukin-8 homologous polypeptides and therapeutic uses thereof
|
US20020099197A1
(en)
*
|
1998-07-21 |
2002-07-25 |
Rory A.J. Curtis |
Novel potassium channel molecules and uses therefor
|
US20030166132A1
(en)
*
|
1998-08-26 |
2003-09-04 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
BR9913285A
(pt)
*
|
1998-08-31 |
2001-05-15 |
Biogen Inc |
Método de modulação das células t efetoras da memória e composições
|
EE04967B1
(et)
*
|
1998-10-16 |
2008-02-15 |
Biogen, Incorporated |
Glkoslitud interferoon-beeta, selle kasutamineja seda sisaldav farmatseutiline kompositsioon, meetod interferoon-beeta-1a aktiivsuse pikendamiseks ja leiutisekohase valgu valmistamiseks
|
MXPA01003790A
(es)
*
|
1998-10-16 |
2002-09-18 |
Biogen Inc |
Proteinas de fusion beta - interferon y sus usos.
|
DE69934425T2
(de)
*
|
1998-10-23 |
2007-09-27 |
Amgen Inc., Thousand Oaks |
Thrombopoietin substitute
|
US7488590B2
(en)
*
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
WO2000027885A1
(fr)
*
|
1998-11-05 |
2000-05-18 |
Kyowa Hakko Kogyo Co., Ltd. |
Nouveau popypeptide chimerique
|
EP1129193A4
(de)
*
|
1998-11-10 |
2005-08-10 |
Human Genome Sciences Inc |
Chemokin beta-7
|
US7294482B2
(en)
*
|
1998-11-19 |
2007-11-13 |
Millennium Pharmaceuticals, Inc. |
EGF-like nucleic acids
|
US7238790B2
(en)
*
|
1999-01-12 |
2007-07-03 |
Genentech, Inc. |
PRO1313 polypeptides
|
AU3224700A
(en)
|
1999-02-08 |
2000-08-25 |
Chiron Corporation |
Fibroblast growth factor receptor-immunoglobulin fusion
|
EP1854480A3
(de)
|
1999-03-19 |
2009-04-01 |
Genentech, Inc. |
Behandlung von LFA-1-assoziierten Krankheiten durch gesteigerte Dosen von LFA-1-Antagonist
|
US7011833B1
(en)
*
|
1999-05-06 |
2006-03-14 |
Genetics Institute, Inc. |
Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent
|
US20050079577A1
(en)
*
|
1999-05-14 |
2005-04-14 |
Ashkenazi Avi J. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
CZ20014123A3
(cs)
*
|
1999-05-19 |
2002-06-12 |
Lexigen Pharmaceuticals Corp. |
Exprese a export interferonů-alfa jako Fc fúzních proteinů
|
CA2375700A1
(en)
*
|
1999-06-01 |
2000-12-07 |
Biogen, Inc. |
Polymer conjugates of hedgehog proteins and uses
|
WO2000073498A1
(en)
*
|
1999-06-02 |
2000-12-07 |
Millennium Pharmaceuticals, Inc. |
Compositions and methods for the treatment and diagnosis of immune disorders
|
US6924359B1
(en)
*
|
1999-07-01 |
2005-08-02 |
Yale University |
Neovascular-targeted immunoconjugates
|
JP2003503426A
(ja)
*
|
1999-07-02 |
2003-01-28 |
ジェネンテック・インコーポレーテッド |
FVIIaアンタゴニスト
|
DE60028970T2
(de)
|
1999-07-02 |
2007-02-15 |
Genentech Inc., San Francisco |
An her2 bindende peptidverbindungen
|
EP1194569A2
(de)
*
|
1999-07-12 |
2002-04-10 |
MERCK PATENT GmbH |
Seripankrin
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
WO2001007084A1
(en)
*
|
1999-07-23 |
2001-02-01 |
Regents Of The University Of California |
Anti-growth factor receptor avidin fusion proteins as universal vectors for drug delivery
|
ATE279437T1
(de)
*
|
1999-08-06 |
2004-10-15 |
Genentech Inc |
Peptidantagonisten des faktors viia
|
US6617135B1
(en)
*
|
1999-08-09 |
2003-09-09 |
Emd Lexigen Research Center Corp. |
Multiple cytokine protein complexes
|
WO2001014557A1
(en)
|
1999-08-23 |
2001-03-01 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
US20030166858A1
(en)
*
|
1999-09-16 |
2003-09-04 |
Samuel Davis |
TIE-2 ligands, methods of making and uses thereof
|
US6323334B1
(en)
|
1999-09-24 |
2001-11-27 |
Millennium Pharmaceuticals, Inc. |
Nucleic acid molecules encoding a 103 gene product and uses therefor
|
AU780693B2
(en)
*
|
1999-11-05 |
2005-04-14 |
Curis, Inc. |
Hedgehog fusion proteins and uses
|
AU2154401A
(en)
|
1999-11-12 |
2001-05-30 |
Merck Patent Gmbh |
Erythropoietin forms with improved properties
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
US7307153B2
(en)
*
|
1999-12-23 |
2007-12-11 |
Genentech, Inc. |
Antibodies that bind PRO9912
|
US7122632B2
(en)
*
|
1999-12-23 |
2006-10-17 |
Zymogenetics, Inc. |
Soluble Interleukin-20 receptor
|
US6610286B2
(en)
|
1999-12-23 |
2003-08-26 |
Zymogenetics, Inc. |
Method for treating inflammation using soluble receptors to interleukin-20
|
US7164001B2
(en)
*
|
2000-01-20 |
2007-01-16 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
DK1252192T3
(da)
|
2000-02-11 |
2006-11-20 |
Merck Patent Gmbh |
Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
|
SK288032B6
(sk)
*
|
2000-02-21 |
2012-12-03 |
Merck Serono Sa |
Use of IL-18 inhibitors for manufacture of medicament for treatment and/or prevention of alcoholic hepatitis
|
US7572631B2
(en)
*
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
US7541184B2
(en)
*
|
2000-02-24 |
2009-06-02 |
Invitrogen Corporation |
Activation and expansion of cells
|
US6984519B2
(en)
|
2000-03-01 |
2006-01-10 |
Genetech, Inc. |
Nucleic acids encoding peptides that induce chondrocyte redifferentiation
|
US20060073547A1
(en)
*
|
2000-03-01 |
2006-04-06 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20060002943A1
(en)
*
|
2000-03-02 |
2006-01-05 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
US20020064820A1
(en)
*
|
2000-03-13 |
2002-05-30 |
Jean-Michel Dayer |
Apo-A-I regulation of T-cell signaling
|
US7514239B2
(en)
*
|
2000-03-28 |
2009-04-07 |
Amgen Inc. |
Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
|
CA2405800A1
(en)
*
|
2000-04-10 |
2001-10-18 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Novel secreted protein
|
US6946134B1
(en)
|
2000-04-12 |
2005-09-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050100991A1
(en)
*
|
2001-04-12 |
2005-05-12 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
CA2405912A1
(en)
*
|
2000-04-12 |
2001-10-18 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
CA2405632A1
(en)
*
|
2000-04-25 |
2001-11-01 |
Idec Pharmaceutical Corporation |
Intrathecal administration of rituximab for treatment of central nervous system lymphomas
|
US6756480B2
(en)
|
2000-04-27 |
2004-06-29 |
Amgen Inc. |
Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
|
EP1290027B1
(de)
*
|
2000-04-28 |
2009-09-09 |
Planet Biotechnology, Inc. |
Immunoadhesin zur impfung gegen rhinovirus
|
US20060015969A1
(en)
*
|
2000-04-28 |
2006-01-19 |
Planet Biotechnology, Inc. |
Novel immunoadhesins for treating and prventing toxicity and pathogen-mediated diseases
|
EP1278778A2
(de)
*
|
2000-05-03 |
2003-01-29 |
Amgen Inc., |
Modifizierte peptide, die eine fc-domäne behalten, als therapeutische agenzien
|
US20020102232A1
(en)
*
|
2000-05-11 |
2002-08-01 |
Chang Tse W. |
Compositions and methods for induction of active autoimmunity
|
RU2270691C2
(ru)
*
|
2000-05-12 |
2006-02-27 |
Бет Израел Диконесс Медикал Сентер, Инк. |
Композиции и способы достижения иммунной супрессии
|
EP1714661A3
(de)
|
2000-05-19 |
2012-03-14 |
The Center for Blood Research, INC. |
Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
|
US20050048614A1
(en)
*
|
2000-06-13 |
2005-03-03 |
Children's Medical Center Corporation |
Biosynthetic oncolytic molecules and uses therefor
|
US20040034193A1
(en)
*
|
2001-06-13 |
2004-02-19 |
Samy Ashkar |
Biosynthetic oncolytic molecules and uses therefor
|
US20030096339A1
(en)
|
2000-06-26 |
2003-05-22 |
Sprecher Cindy A. |
Cytokine receptor zcytor17
|
WO2002000721A2
(en)
*
|
2000-06-26 |
2002-01-03 |
Zymogenetics, Inc. |
Cytokine receptor zcytor17
|
WO2002000692A2
(en)
|
2000-06-28 |
2002-01-03 |
Genetics Institute, Llc. |
Pd-l2 molecules: pd-1 ligands and uses therefor
|
BR0112111A
(pt)
*
|
2000-06-29 |
2003-05-06 |
Merck Patent Gmbh |
Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
EP1337636B1
(de)
*
|
2000-08-08 |
2006-10-18 |
ZymoGenetics, Inc. |
Lösliche zcyctor 11 cytokinrezeptoren
|
US20030215916A1
(en)
*
|
2000-08-18 |
2003-11-20 |
Feder John N. |
Novel imidazoline receptor homologs
|
US20020119148A1
(en)
|
2000-09-01 |
2002-08-29 |
Gerritsen Mary E. |
ErbB4 antagonists
|
CA2417432C
(en)
|
2000-09-01 |
2010-11-02 |
The Center For Blood Research, Inc. |
Modified polypeptides stabilized in a desired conformation and methods for producing same
|
MXPA03002278A
(es)
*
|
2000-09-14 |
2004-12-03 |
Beth Israel Hospital |
Modulacion de respuestas de la celula t mediadas por il-2 e il-15.
|
AU2002214545B2
(en)
|
2000-09-26 |
2008-04-03 |
Genentech, Inc. |
IGE receptor antagonists
|
WO2002026986A2
(en)
*
|
2000-09-29 |
2002-04-04 |
Bristol-Myers Squibb Company |
Identification and cloning of a full-length human cink-related gene, mist (mast cell immunoreceptor signal transducer)
|
US20030211549A1
(en)
*
|
2000-10-06 |
2003-11-13 |
Murphy Andrew J. |
Functional proteins and therapeutic and diagnostic methods for use thereof
|
EP1364019A2
(de)
*
|
2000-11-07 |
2003-11-26 |
Board of Regents, The University of Texas System |
Verfahren und zusammensetzungen bezogen auf muskelnspezifischen sarkomerischen calcineurinbindungsproteine (calsarine)
|
AU2002216481B2
(en)
*
|
2000-12-04 |
2008-05-01 |
Auckland Uniservices Limited |
Immunomodulatory constructs and their uses
|
US7396917B2
(en)
|
2000-12-05 |
2008-07-08 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
US20040253242A1
(en)
*
|
2000-12-05 |
2004-12-16 |
Bowdish Katherine S. |
Rationally designed antibodies
|
ES2380367T3
(es)
*
|
2000-12-05 |
2012-05-11 |
Alexion Pharmaceuticals, Inc. |
Anticuerpos diseñados racionalmente
|
WO2002066606A2
(en)
*
|
2001-02-16 |
2002-08-29 |
Bristol-Myers Squibb Company |
Polynucleotides encoding a novel glycine receptor alpha subunit expressed in the gastrointestinal tract, hgra4, and splice variant thereof
|
MXPA03008031A
(es)
*
|
2001-03-07 |
2003-12-04 |
Merck Patent Gmbh |
Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
|
AU2002250293B2
(en)
|
2001-03-09 |
2007-10-11 |
Arnason, Barry G. Mr |
Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors
|
US8163289B2
(en)
|
2001-03-09 |
2012-04-24 |
Iterative Therapeutics, Inc. |
Methods and compositions involving polymeric immunoglobulin fusion proteins
|
WO2002079415A2
(en)
*
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
EP2388590A1
(de)
|
2001-04-02 |
2011-11-23 |
Dana Farber Cancer Institute |
PD-1, ein Rezeptor für B7-4, und Verwendungen dafür
|
US7507413B2
(en)
|
2001-04-12 |
2009-03-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050244931A1
(en)
*
|
2001-04-12 |
2005-11-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050054051A1
(en)
*
|
2001-04-12 |
2005-03-10 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20060084794A1
(en)
*
|
2001-04-12 |
2006-04-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
ITRE20010042A1
(it)
*
|
2001-04-24 |
2002-10-24 |
Corghi Spa |
Dispositivo sollevatore per macchine smontagomme
|
US20050089932A1
(en)
*
|
2001-04-26 |
2005-04-28 |
Avidia Research Institute |
Novel proteins with targeted binding
|
US7265208B2
(en)
*
|
2001-05-01 |
2007-09-04 |
The Regents Of The University Of California |
Fusion molecules and treatment of IgE-mediated allergic diseases
|
DK1383785T3
(da)
*
|
2001-05-03 |
2011-05-23 |
Merck Patent Gmbh |
Rekombinant tumorspecifikt antistof og anvendelse deraf
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
EE05294B1
(et)
|
2001-05-11 |
2010-04-15 |
Amgen Inc. |
TALL-1-ga seostuv ainekompositsioon
|
US20040198961A1
(en)
*
|
2001-06-15 |
2004-10-07 |
Ling-Ling An |
Fce fusion proteins for treatment of allergy and asthma
|
US20060073141A1
(en)
*
|
2001-06-28 |
2006-04-06 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
EP1419236A4
(de)
*
|
2001-07-24 |
2005-08-03 |
Biogen Idec Inc |
Verfahren zur behandlung von sklerotischen erkrankungen unter verwendung cd2-bindender substanzen
|
CA2456470A1
(en)
*
|
2001-08-13 |
2003-02-27 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
US6900292B2
(en)
*
|
2001-08-17 |
2005-05-31 |
Lee-Hwei K. Sun |
Fc fusion proteins of human erythropoietin with increased biological activities
|
CN101884784B
(zh)
|
2001-08-29 |
2014-03-12 |
杰南技术公司 |
具有促细胞分裂活性的Bv8的核酸和多肽
|
CN1628126A
(zh)
*
|
2001-08-30 |
2005-06-15 |
比奥雷克西斯药物公司 |
经修饰的运铁蛋白融合蛋白
|
US6797493B2
(en)
|
2001-10-01 |
2004-09-28 |
Lee-Hwei K. Sun |
Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
|
AU2002332041A1
(en)
*
|
2001-10-05 |
2003-04-22 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US7138370B2
(en)
*
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
US7205275B2
(en)
*
|
2001-10-11 |
2007-04-17 |
Amgen Inc. |
Methods of treatment using specific binding agents of human angiopoietin-2
|
JP2005506073A
(ja)
*
|
2001-10-19 |
2005-03-03 |
ザイモジェネティクス,インコーポレイティド |
二量体化された成長因子及びそれを生成するための材料及び方法
|
EP1446158B1
(de)
*
|
2001-10-25 |
2010-07-07 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Effiziente hemmung des eintritts von hiv-1-virus durch ein neues fusionsprotein mit cd4
|
US20070118934A1
(en)
*
|
2001-10-26 |
2007-05-24 |
Planet Biotechnology, Inc. |
Chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
|
AU2002357784B2
(en)
*
|
2001-12-04 |
2008-07-31 |
Merck Patent Gmbh |
Immunocytokines with modulated selectivity
|
DE60234713D1
(de)
*
|
2001-12-18 |
2010-01-21 |
Endocube Sas |
Neue mit dem zelltod assoziierte proteine aus der thap familie und par4 verwandte signalwege, die bei der kontrolle von apoptosis involviert sind
|
US7858297B2
(en)
*
|
2001-12-18 |
2010-12-28 |
Centre National De La Recherche Scientifique Cnrs |
Chemokine-binding protein and methods of use
|
KR101271635B1
(ko)
*
|
2001-12-21 |
2013-06-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
알부민 융합 단백질
|
AU2002364587A1
(en)
*
|
2001-12-21 |
2003-07-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
WO2005003296A2
(en)
|
2003-01-22 |
2005-01-13 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
ES2545090T3
(es)
*
|
2001-12-21 |
2015-09-08 |
Human Genome Sciences, Inc. |
Proteínas de fusión de albúmina y GCSF
|
PL213322B1
(pl)
|
2002-01-18 |
2013-02-28 |
Biogen Idec Inc |
Kompozycja farmaceutyczna zawierajaca polimer glikolu polialkilenowego skoniugowany z biologicznie aktywnym zwiazkiem lub jego prekursorem oraz jej zastosowania
|
BR0306979A
(pt)
|
2002-01-18 |
2004-11-23 |
Zymogenetics Inc |
Polipeptìdeo isolado, proteìna de fusão, molécula isolada de polinucleotìdeo, vetor de expressão, célula cultivada, anticorpo ou fragmento de anticorpo, e, métodos para produzir uma proteìna, para produzir um anticorpo, para estimular uma resposta imune em um mamìfero, para expandir células hematopoiéticas e progenitores de células hematopoiéticas, para detectar a presença de rna zcytor17lig e de zcytor17lig em uma amostra biológica, para matar cérlulas cancerìgenas, para inibir a proliferação induzida por zcytor17lig ou diferenciação de células hematopoiéticas e progenitoras de células hematopoiéticas, para reduzir a inflamação induzida por zcytor17lig para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero acometido por uma doença inflamatória e para detectar inflamação em um paciente
|
US7164002B2
(en)
|
2002-02-06 |
2007-01-16 |
Genentech, Inc. |
FVIIa antagonists
|
US20030211470A1
(en)
*
|
2002-03-15 |
2003-11-13 |
Olson William C. |
CD4-IgG2-based salvage therapy of HIV-1 infection
|
RS89104A
(en)
*
|
2002-04-10 |
2006-12-15 |
Applied Research Systems Ars Holding N.V. |
Novel antagonists of mcp proteins
|
US20040016010A1
(en)
*
|
2002-04-17 |
2004-01-22 |
Marion Kasaian |
IL-21 receptor knockout animal and methods of use thereof
|
CN100562573C
(zh)
|
2002-05-29 |
2009-11-25 |
雅玛山酱油株式会社 |
新的多磷酸amp磷酸转移酶
|
DE60334453D1
(de)
*
|
2002-05-30 |
2010-11-18 |
Macrogenics Inc |
Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
|
NZ519371A
(en)
*
|
2002-06-04 |
2004-11-26 |
Auckland Uniservices Ltd |
Immunomodulatory constructs and their uses
|
EP1369128A1
(de)
*
|
2002-06-07 |
2003-12-10 |
Procorde GmbH |
Glycoprotein VI Inhibitoren und deren therapeutische Verwendung
|
US7531178B2
(en)
*
|
2002-06-07 |
2009-05-12 |
Trigen Gmbh |
Immunoadhesin comprising a glycoprotein VI domain
|
US20090130021A1
(en)
*
|
2002-06-07 |
2009-05-21 |
Gotz Munch |
Methods, products and uses involving platelets and/or the vasculature
|
US20070071744A1
(en)
*
|
2002-06-07 |
2007-03-29 |
Gotz Munch |
Agents which bind to epitopes of glycoprotein VI
|
US8025873B2
(en)
|
2002-06-20 |
2011-09-27 |
Paladin Labs, Inc. |
Chimeric antigens for eliciting an immune response
|
US8029803B2
(en)
|
2002-06-20 |
2011-10-04 |
Paladin Labs, Inc. |
Chimeric antigens for eliciting an immune response
|
US20070104710A1
(en)
*
|
2002-06-28 |
2007-05-10 |
Domants Limited |
Ligand that has binding specificity for IL-4 and/or IL-13
|
JP2006512895A
(ja)
*
|
2002-06-28 |
2006-04-20 |
ドマンティス リミテッド |
リガンド
|
WO2004002417A2
(en)
|
2002-06-28 |
2004-01-08 |
Centocor, Inc. |
Mammalian ch1 deleted mimetibodies, compositions, methods and uses
|
CN1241946C
(zh)
*
|
2002-07-01 |
2006-02-15 |
美国福源集团 |
对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
|
JP5068931B2
(ja)
*
|
2002-07-12 |
2012-11-07 |
ザ ジョンズ ホプキンス ユニバーシティー |
独自のクローン形質のリンパ球受容体に結合する試薬および方法
|
CN1688340A
(zh)
|
2002-07-15 |
2005-10-26 |
韦思公司 |
调节t辅助(th)细胞发育和功能的方法和组合物
|
US20040110681A1
(en)
*
|
2002-08-08 |
2004-06-10 |
Xiao-Min Fan |
Method to identify targeting molecules
|
PL376536A1
(pl)
|
2002-08-28 |
2006-01-09 |
Immunex Corporation |
Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego
|
DE10251463A1
(de)
*
|
2002-11-05 |
2004-05-19 |
BSH Bosch und Siemens Hausgeräte GmbH |
Elektrisch angetriebene Pumpe
|
US20050054054A1
(en)
*
|
2002-11-12 |
2005-03-10 |
Foss Francine M. |
Interleukin-7 molecules with altered biological properties
|
JP4494977B2
(ja)
*
|
2002-12-17 |
2010-06-30 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Gd2に結合するマウス14.18抗体のヒト化抗体(h14.18)およびそのil−2融合タンパク質
|
GB0230203D0
(en)
*
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
AU2003290330A1
(en)
*
|
2002-12-27 |
2004-07-22 |
Domantis Limited |
Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
|
US20110223168A1
(en)
*
|
2002-12-27 |
2011-09-15 |
Greg Winter |
Ligand that has binding specificity for il-4 and/or il-13
|
EP1596804A4
(de)
*
|
2003-01-13 |
2008-02-06 |
Macrogenics Inc |
LÖSLICHE FcyR-FUSIONSPROTEINE UND VERFAHREN ZU IHRER ANWENDUNG
|
CA2514834A1
(en)
*
|
2003-02-06 |
2004-08-19 |
Novozymes A/S |
Human heavy chain antibody expression in filamentous fungi
|
US20050096264A1
(en)
*
|
2003-02-25 |
2005-05-05 |
Macdonald Lynn |
Methods for treating obesity and related conditions with glycoprotein hormone beta family hormones
|
MXPA05009743A
(es)
|
2003-03-12 |
2006-03-09 |
Genentech Inc |
Composiciones con actividad hematopoyetica e inmune.
|
WO2004084816A2
(en)
*
|
2003-03-21 |
2004-10-07 |
Progenics Pharmaceuticals, Inc. |
IMPROVED CD4-IgG2 FORMULATIONS
|
EA009124B1
(ru)
*
|
2003-03-24 |
2007-10-26 |
Займоджинетикс, Инк. |
Антитела против il-20 и связывающие партнеры, а также способы их применения при воспалении
|
ES2327409T3
(es)
|
2003-03-26 |
2009-10-29 |
Apogenix Gmbh |
Proteinas de fusion fc mejoradas.
|
TWI353991B
(en)
*
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
US20050037947A1
(en)
*
|
2003-05-06 |
2005-02-17 |
Bitonti Alan J. |
Inhibition of drug binding to serum albumin
|
ATE497783T1
(de)
*
|
2003-05-06 |
2011-02-15 |
Syntonix Pharmaceuticals Inc |
Gerinnungsfaktor vii-fc chimäre proteine zur behandlung von hämostatischen krankheiten
|
US7348004B2
(en)
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
US7429378B2
(en)
*
|
2003-05-13 |
2008-09-30 |
Depuy Spine, Inc. |
Transdiscal administration of high affinity anti-MMP inhibitors
|
JP2007502327A
(ja)
|
2003-05-13 |
2007-02-08 |
デピュイ スパイン、インコーポレイテッド |
椎間板変性症の治療法
|
US7553827B2
(en)
*
|
2003-08-13 |
2009-06-30 |
Depuy Spine, Inc. |
Transdiscal administration of cycline compounds
|
US8273347B2
(en)
*
|
2003-05-13 |
2012-09-25 |
Depuy Spine, Inc. |
Autologous treatment of degenerated disc with cells
|
PT1622939E
(pt)
*
|
2003-05-13 |
2012-03-28 |
Merck Serono Sa |
Variantes ativas da proteína de ligação à il-18 e suas utilizações médicas
|
US20040229878A1
(en)
*
|
2003-05-13 |
2004-11-18 |
Depuy Spine, Inc. |
Transdiscal administration of specific inhibitors of P38 kinase
|
US7344716B2
(en)
*
|
2003-05-13 |
2008-03-18 |
Depuy Spine, Inc. |
Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
|
US7435808B2
(en)
|
2003-06-25 |
2008-10-14 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel adiponectin receptor variant, AdipoR2v2
|
PL1639011T3
(pl)
*
|
2003-06-30 |
2009-05-29 |
Domantis Ltd |
Pegilowane przeciwciała jednodomenowe (dAb)
|
US7569215B2
(en)
*
|
2003-07-18 |
2009-08-04 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
US8361467B2
(en)
*
|
2003-07-30 |
2013-01-29 |
Depuy Spine, Inc. |
Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
|
US8007805B2
(en)
*
|
2003-08-08 |
2011-08-30 |
Paladin Labs, Inc. |
Chimeric antigens for breaking host tolerance to foreign antigens
|
EP2520654B8
(de)
|
2003-08-26 |
2017-04-19 |
The Regents of the University of Colorado, a body corporate |
Serinprotease-Hemmer und deren Verwendung in Verfahren und Zusammensetzungen für die Behandlung bakterieller Infektionen
|
US20050069521A1
(en)
*
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
UA89481C2
(uk)
*
|
2003-09-30 |
2010-02-10 |
Центокор, Инк. |
Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
|
US20070274988A1
(en)
*
|
2003-10-10 |
2007-11-29 |
Five Prime Therapeautics, Inc. |
Kiaa0779, Splice Variants Thereof, and Methods of Their Use
|
US20050239700A1
(en)
*
|
2003-10-14 |
2005-10-27 |
Biogen Idec Inc. |
Treatment of cancer using antibodies to LRRC15
|
WO2005042573A1
(en)
*
|
2003-10-24 |
2005-05-12 |
Dana-Farber Cancer Institute, Inc. |
Modulation of the interaction of muc1 with muc1 ligands
|
JP2008504002A
(ja)
|
2003-11-12 |
2008-02-14 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
新生児Fcレセプター(FcRn)結合ポリペプチド改変体、ダイマーFc結合タンパク質、およびそれらに関連する方法
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
KR20050047030A
(ko)
|
2003-11-13 |
2005-05-19 |
한미약품 주식회사 |
약물의 캐리어로서 유용한 IgG Fc 단편 및 그의제조방법
|
US8895540B2
(en)
*
|
2003-11-26 |
2014-11-25 |
DePuy Synthes Products, LLC |
Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
|
BRPI0418286A
(pt)
|
2003-12-30 |
2007-05-02 |
Merck Patent Gmbh |
proteìnas de fusão de il-7
|
KR20060124656A
(ko)
*
|
2003-12-31 |
2006-12-05 |
메르크 파텐트 게엠베하 |
개선된 약물동태를 가지는 Fc-에리스로포이에틴 융합단백질
|
EP1706428B1
(de)
|
2004-01-22 |
2009-09-23 |
MERCK PATENT GmbH |
Antikrebs-antikörper mit reduzierter komplementfixierung
|
WO2005077018A2
(en)
*
|
2004-02-06 |
2005-08-25 |
Astellas Us Llc |
Methods of treating skin disorders
|
NZ549040A
(en)
*
|
2004-02-17 |
2009-07-31 |
Schering Corp |
Use for interleukin-33 (IL33) and the IL-33 receptor complex
|
US20100028995A1
(en)
*
|
2004-02-23 |
2010-02-04 |
Anaphore, Inc. |
Tetranectin Trimerizing Polypeptides
|
MXPA06011425A
(es)
*
|
2004-03-31 |
2007-03-12 |
Johnson & Johnson |
Memiticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos.
|
US20080020383A1
(en)
*
|
2004-05-04 |
2008-01-24 |
Genaissance Pharmaceuticals, Inc. |
Haplotype Markers And Methods Of Using The Same To Determine Response To Treatment
|
EP1750747A1
(de)
*
|
2004-05-07 |
2007-02-14 |
Astellas US LLC |
Lösliches lfa-3 polypeptid zur behandlung viraler erkrankungen
|
US20060063208A1
(en)
*
|
2004-08-02 |
2006-03-23 |
Woolf Clifford J |
DRG11-responsive (DRAGON) gene and uses thereof
|
US7393662B2
(en)
|
2004-09-03 |
2008-07-01 |
Centocor, Inc. |
Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
|
EP1804835B9
(de)
|
2004-09-13 |
2012-05-02 |
Genzyme Corporation |
Multimere konstrukte
|
DK1797127T3
(en)
*
|
2004-09-24 |
2017-10-02 |
Amgen Inc |
Modified Fc molecules
|
ES2390676T3
(es)
|
2004-10-21 |
2012-11-15 |
Genentech, Inc. |
Método para el tratamiento de enfermedades neovasculares intraoculares
|
CA2584157C
(en)
|
2004-10-22 |
2014-10-14 |
Zymogenetics, Inc. |
Anti-il-22ra antibodies and binding partners and methods of using in inflammation
|
US20090311259A1
(en)
*
|
2004-11-17 |
2009-12-17 |
Victoria Smith |
Compositions and Methods for Treatment of Tumor of Hematopoietic Origin
|
KR20070085886A
(ko)
*
|
2004-12-09 |
2007-08-27 |
메르크 파텐트 게엠베하 |
감소된 면역원성의 il-7 변이체
|
CN100515491C
(zh)
*
|
2005-01-04 |
2009-07-22 |
健能隆医药技术(上海)有限公司 |
白介素-22的医药用途
|
JP2008526234A
(ja)
|
2005-01-05 |
2008-07-24 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Cripto結合分子
|
DE602006017071D1
(de)
|
2005-01-25 |
2010-11-04 |
Five Prime Therapeutics Inc |
Zusammensetzungen und verfahren zur behandlung von herzkrankheiten
|
WO2006084327A1
(en)
*
|
2005-02-09 |
2006-08-17 |
Apollo Life Sciences Limited |
A molecule and chimeric molecules thereof
|
KR100754667B1
(ko)
|
2005-04-08 |
2007-09-03 |
한미약품 주식회사 |
비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
|
US9284375B2
(en)
*
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
ES2707152T3
(es)
|
2005-04-15 |
2019-04-02 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
ES2561628T3
(es)
|
2005-05-06 |
2016-02-29 |
Zymogenetics, Inc. |
Anticuerpos monoclonales IL-31 y métodos de uso
|
WO2006138553A2
(en)
|
2005-06-17 |
2006-12-28 |
Wyeth |
Methods of purifying fc region containing proteins
|
HUE042561T2
(hu)
|
2005-06-30 |
2019-07-29 |
Janssen Biotech Inc |
Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
|
BRPI0613387A2
(pt)
|
2005-07-08 |
2011-01-11 |
Biogen Idec Inc |
anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
US7713521B2
(en)
*
|
2005-08-12 |
2010-05-11 |
Schering Corporation |
MCP1 fusions
|
KR20080050591A
(ko)
|
2005-09-01 |
2008-06-09 |
아레스 트레이딩 에스.에이. |
시신경염 치료
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
JP2009511024A
(ja)
*
|
2005-10-13 |
2009-03-19 |
ヴィレックス メディカル コーポレイション |
免疫応答を誘導するためのC型肝炎ウイルスポリペプチドおよびFcフラグメントを含むキメラ抗原
|
TW200722436A
(en)
*
|
2005-10-21 |
2007-06-16 |
Hoffmann La Roche |
A peptide-immunoglobulin-conjugate
|
WO2007058776A2
(en)
*
|
2005-11-10 |
2007-05-24 |
Receptor Biologix, Inc. |
Hepatocyte growth factor intron fusion proteins
|
PT2380592T
(pt)
|
2005-11-14 |
2018-06-06 |
Teva Pharmaceuticals Int Gmbh |
Anticorpos antagonistas dirigidos contra o péptido relacionado com o gene da calcitonina e métodos utilizando os mesmos
|
AU2006321364B2
(en)
*
|
2005-12-01 |
2011-11-10 |
Domantis Limited |
Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
|
WO2007064911A1
(en)
*
|
2005-12-02 |
2007-06-07 |
Biogen Idec Inc. |
Anti-mouse cd20 antibodies and uses thereof
|
WO2007078615A2
(en)
*
|
2005-12-15 |
2007-07-12 |
Cavit Sciences, Inc |
Methods and compositions for treatment of cancer
|
CA2634262A1
(en)
*
|
2005-12-22 |
2007-07-05 |
Dhy & Co., Ltd |
Antibodies against interleukin-22 binding protein and its uses
|
DK3219328T3
(da)
|
2005-12-29 |
2020-07-13 |
Janssen Biotech Inc |
Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser
|
ATE555125T1
(de)
*
|
2005-12-30 |
2012-05-15 |
Merck Patent Gmbh |
Interleukin-12p40-varianten mit verbesserter stabilität
|
JP2009521912A
(ja)
|
2005-12-30 |
2009-06-11 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
低減された免疫原性を有する抗cd19抗体
|
CA2636288C
(en)
|
2006-01-10 |
2015-02-24 |
Zymogenetics, Inc. |
Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
|
US7625564B2
(en)
*
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
US20070179094A1
(en)
|
2006-01-31 |
2007-08-02 |
Bayer Schering Pharma Ag |
Modulation of MDL-1 activity for treatment of inflammatory disease
|
GB0604187D0
(en)
*
|
2006-03-02 |
2006-04-12 |
Fusion Antibodies Ltd |
Peptide and uses thereof
|
EP2007538A4
(de)
*
|
2006-03-31 |
2011-04-20 |
Centocor Ortho Biotech Inc |
Bindungspartner mit modifzierten immunglobulindomänen für verlängerte halbwertzeit
|
JP2009537605A
(ja)
|
2006-05-24 |
2009-10-29 |
メルク セローノ ソシエテ アノニム |
多発性硬化症を治療するためのクラドリビン・レジメン
|
US20100055093A1
(en)
*
|
2006-06-12 |
2010-03-04 |
Receptor Biologix Inc. |
Pan-cell surface receptor-specific therapeutics
|
CN101505793A
(zh)
*
|
2006-06-22 |
2009-08-12 |
瓦西尼斯公司 |
用于治疗癌症的抗c35抗体
|
US20100021379A1
(en)
*
|
2006-06-29 |
2010-01-28 |
The Regents Of The University Of California |
Chemical Antibodies for Immunotherapy and Imaging
|
WO2008008373A2
(en)
|
2006-07-11 |
2008-01-17 |
Arubor Corp |
Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
|
US20080014285A1
(en)
*
|
2006-07-13 |
2008-01-17 |
Di Mauro Thomas M |
Method of treating neurodegenerative brain disease with a composite comprising superparamagnetic nanoparticles and a therapeutic compound
|
JP2010500360A
(ja)
|
2006-08-10 |
2010-01-07 |
アルボア コーポレーション |
炎症性サイトカイン阻害剤による下気道炎症疾患の局所療法
|
WO2008020079A1
(en)
|
2006-08-18 |
2008-02-21 |
Ablynx N.V. |
Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
|
US7767206B2
(en)
|
2006-10-02 |
2010-08-03 |
Amgen Inc. |
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
|
WO2008042436A2
(en)
|
2006-10-03 |
2008-04-10 |
Biogen Idec Ma Inc. |
Biomarkers and assays for the treatment of cancer
|
MX2009004664A
(es)
|
2006-11-02 |
2009-10-12 |
Daniel J Capon |
Inmunoglobulinas hibridas con partes moviles.
|
CL2007003411A1
(es)
|
2006-11-28 |
2008-07-04 |
Centelion |
Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
|
SI2436696T1
(sl)
|
2007-01-05 |
2017-10-30 |
University Of Zurich |
Anti-beta-amiloidno protitelo in načini njegove uporabe
|
DK2068887T3
(da)
|
2007-01-09 |
2014-05-19 |
Biogen Idec Inc |
SP35-antistoffer og anvendelser heraf
|
CN104189885A
(zh)
|
2007-02-23 |
2014-12-10 |
纽约哥伦比亚大学理事会 |
通过激活或阻断HLA-E/Qa-1限制性CD8+T细胞调控途径治疗免疫疾病的方法
|
WO2008112092A2
(en)
*
|
2007-03-07 |
2008-09-18 |
Glycofi, Inc. |
Production of glycoproteins with modified fucosylation
|
CN104109200B
(zh)
|
2007-05-11 |
2018-03-20 |
阿尔托生物科学有限公司 |
融合分子与il‑15变异体
|
US7906149B2
(en)
*
|
2007-05-25 |
2011-03-15 |
Boval Company, L.P. |
Method for treating allergic dermatitis
|
EP2164508B1
(de)
*
|
2007-06-04 |
2014-01-08 |
Rappaport Family Institute for Research in the Medical Sciences |
Mittel zur behandlung von entzündlichen erkrankungen und anwendungsverfahren dafür
|
WO2008149147A2
(en)
*
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Polypeptides, antibody variable domains and antagonists
|
US8067548B2
(en)
*
|
2007-07-26 |
2011-11-29 |
Novagen Holding Corporation |
Fusion proteins having mutated immunoglobulin hinge region
|
GB0717337D0
(en)
*
|
2007-09-06 |
2007-10-17 |
Ucb Pharma Sa |
Method of treatment
|
AU2008310263B2
(en)
|
2007-10-11 |
2014-09-11 |
University Health Network |
Modulation of SIRPALPHA - CD47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
|
KR20100082775A
(ko)
*
|
2007-10-16 |
2010-07-19 |
심포젠 에이/에스 |
최적화된 her1 및 her3 멀티머를 포함하는 조성물 및 그것의 사용 방법
|
KR101383476B1
(ko)
|
2007-11-01 |
2014-04-11 |
아스테라스 세이야쿠 가부시키가이샤 |
면역억제 폴리펩티드 및 핵산
|
US8906356B2
(en)
*
|
2007-11-05 |
2014-12-09 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
EP2217261B1
(de)
|
2007-11-09 |
2015-10-07 |
Genentech, Inc. |
Activin-rezeptor-like-kinase-1-antagonist-zusammensetzungen und anwendungsverfahren
|
SI3002298T1
(sl)
|
2007-11-21 |
2019-12-31 |
Oregon Health & Science University |
Monoklonska protitelesa proti faktorju XI in postopki njihove uporabe
|
US20090312249A1
(en)
*
|
2007-12-06 |
2009-12-17 |
Korea Advanced Institute Of Science And Technology |
TLR4 decoy receptor protein
|
KR101603109B1
(ko)
|
2007-12-07 |
2016-03-25 |
지모제넥틱스, 인코포레이티드 |
Il-31에 특이적인 인간화된 항체 분자
|
US20090162351A1
(en)
*
|
2007-12-21 |
2009-06-25 |
Depuy Spine, Inc. |
Transdiscal administration of inhibitors of p38 MAP kinase
|
US8986696B2
(en)
*
|
2007-12-21 |
2015-03-24 |
Depuy Mitek, Inc. |
Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
|
US8293239B2
(en)
|
2008-03-04 |
2012-10-23 |
Pfizer Limited |
Methods of treating chronic pain
|
EP3045475B1
(de)
|
2008-04-02 |
2017-10-04 |
MacroGenics, Inc. |
Bcr-komplex-spezifische antikorper und verfahren zu ihrer verwendung
|
ES2620285T3
(es)
*
|
2008-05-02 |
2017-06-28 |
Novartis Ag |
Moléculas de unión con base en fibronectina mejorada y usos de las mismas
|
PL2280996T3
(pl)
|
2008-05-06 |
2017-07-31 |
Genentech Inc |
WARIANTY CRIg O DOJRZAŁYM POWINOWACTWIE
|
CA2726845C
(en)
*
|
2008-06-04 |
2017-09-26 |
Macrogenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
NZ590605A
(en)
|
2008-07-09 |
2012-11-30 |
Biogen Idec Inc |
Compositions comprising antibodies to lingo or fragments thereof
|
TWI388570B
(zh)
|
2008-07-23 |
2013-03-11 |
Hanmi Science Co Ltd |
包含具有三個官能端的非肽醯聚合物的多肽複合物
|
US20100159485A1
(en)
*
|
2008-12-19 |
2010-06-24 |
Centre For Dna Fingerprinting And Diagnostics |
Detection of mycobacterium tuberculosis
|
HUE025150T2
(en)
|
2008-12-19 |
2016-01-28 |
Biogen Int Neuroscience Gmbh |
Human anti-alpha-synuclein autoantibodies
|
WO2010078526A1
(en)
|
2008-12-31 |
2010-07-08 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
RU2542394C2
(ru)
|
2009-03-24 |
2015-02-20 |
ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. |
Гуманизированные антитела против light и их применение
|
KR101766927B1
(ko)
|
2009-04-01 |
2017-08-09 |
제넨테크, 인크. |
인슐린 저항성 장애의 치료
|
JP5647222B2
(ja)
|
2009-04-10 |
2014-12-24 |
アブリンクス エン.ヴェー. |
Il−6r関連疾患及び障害の治療のためのil−6rに指向性を有する改善されたアミノ酸配列及びこれを含むポリペプチド
|
WO2010115995A2
(en)
|
2009-04-10 |
2010-10-14 |
Ablynx Nv |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
JP5727459B2
(ja)
|
2009-04-22 |
2015-06-03 |
アルテオゼン, インクAlteogen, Inc |
体内持続性を維持することにより体内半減期が増加したタンパク質またはペプチド融合体
|
AU2010238858A1
(en)
|
2009-04-22 |
2011-12-08 |
Merck Patent Gmbh |
Antibody fusion proteins with modified FcRn binding sites
|
KR101754433B1
(ko)
|
2009-05-08 |
2017-07-05 |
백시넥스 인코포레이티드 |
항-cd100 항체 및 이의 사용 방법
|
DK2995315T3
(da)
|
2009-05-15 |
2024-02-19 |
Univ Health Network |
Sammensætninger og fremgangsmåder til behandling af hæmatologiske cancerformer med sigte på interaktion mellem Sirp alpha og CD47
|
JP5784010B2
(ja)
|
2009-06-15 |
2015-09-24 |
バイオカイン セラピューティックス リミテッド |
自己免疫性、炎症およびガンの経過を阻害し得る新規なケモカイン結合ポリペプチド
|
WO2011019620A1
(en)
|
2009-08-10 |
2011-02-17 |
Genentech, Inc. |
Antibodies with enhanced adcc function
|
WO2011019622A1
(en)
|
2009-08-14 |
2011-02-17 |
Genentech, Inc. |
Cell culture methods to make antibodies with enhanced adcc function
|
KR101519192B1
(ko)
|
2009-08-28 |
2015-05-11 |
리나트 뉴로사이언스 코프. |
칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
|
JP5898082B2
(ja)
|
2009-10-07 |
2016-04-06 |
マクロジェニクス,インコーポレーテッド |
フコシル化程度の変更により改良されたエフェクター機能を示すFc領域含有ポリペプチドおよびその使用法
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
US20110165122A1
(en)
*
|
2009-11-10 |
2011-07-07 |
The Regents Of The University Of California |
Method for targeted and sustained antiviral therapy
|
US20120269830A1
(en)
|
2009-12-07 |
2012-10-25 |
Lawrence Horowitz |
Conjugates with improved pharmacokinetic properties
|
EP2516467A2
(de)
|
2009-12-23 |
2012-10-31 |
Emergent Product Development Seattle, LLC |
Zusammensetzungen mit tnf-alpha- und il-6-antagonisten und verwendungsverfahren dafür
|
US8637637B2
(en)
|
2010-01-12 |
2014-01-28 |
Bill Nai-Chau Sun |
Fc fusion proteins of human growth hormone
|
LT2523688T
(lt)
|
2010-01-15 |
2018-03-12 |
Kirin-Amgen, Inc. |
Antikūno kompozicija ir terapiniai režimai
|
WO2011103164A1
(en)
|
2010-02-18 |
2011-08-25 |
Centocor Ortho Biotech Inc. |
Monkey homolog of human interferon omega
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
PE20130479A1
(es)
|
2010-03-04 |
2013-05-12 |
Macrogenics Inc |
Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos
|
WO2011109280A1
(en)
|
2010-03-05 |
2011-09-09 |
Lerner Research Institute |
Methods and compositions to treat immune-mediated disorders
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
CA3079122A1
(en)
|
2010-03-26 |
2011-09-29 |
Trustees Of Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
US20110245469A1
(en)
*
|
2010-04-02 |
2011-10-06 |
Athena Discovery, Inc. |
Intermediates formed in biosynthesis of relaxin-fusion proteins with extended in vivo half-lives
|
WO2011130533A1
(en)
|
2010-04-16 |
2011-10-20 |
Centocor Ortho Biotech Inc. |
Engineered plant cysteine proteases and their uses
|
US8524217B2
(en)
|
2010-05-11 |
2013-09-03 |
Merck Sharp & Dohme Corp. |
MCP1-Ig fusion variants
|
EP2582387A2
(de)
|
2010-06-17 |
2013-04-24 |
The United States Of America As Represented By The Secretary, National Institutes Of Health |
Zusammensetzungen und verfahren zur behandlung von entzündungserkrankungen
|
WO2012006623A1
(en)
|
2010-07-09 |
2012-01-12 |
Biogen Idec Hemophilia Inc. |
Systems for factor viii processing and methods thereof
|
CN103154025B
(zh)
|
2010-08-02 |
2015-07-01 |
宏观基因有限公司 |
共价双抗体及其用途
|
ES2652508T3
(es)
|
2010-08-06 |
2018-02-02 |
Genzyme Corporation |
Composiciones de antagonistas de VEGF y sus usos
|
AU2011295902B2
(en)
|
2010-09-02 |
2014-12-04 |
Vaccinex, Inc. |
Anti-CXCL13 antibodies and methods of using the same
|
CN107880136B
(zh)
|
2010-09-21 |
2021-11-12 |
阿尔托生物科学有限公司 |
多聚体il-15可溶性融合分子与其制造与使用方法
|
US11053299B2
(en)
|
2010-09-21 |
2021-07-06 |
Immunity Bio, Inc. |
Superkine
|
JP6126991B2
(ja)
|
2010-09-27 |
2017-05-10 |
ヤンセン バイオテツク,インコーポレーテツド |
ヒトii型コラーゲンに結合する抗体
|
EA031698B1
(ru)
|
2010-10-11 |
2019-02-28 |
Байоджен Интернэшнл Нейросайенз Гмбх |
Человеческие анти-тау антитела
|
US8883134B2
(en)
*
|
2010-10-20 |
2014-11-11 |
Handok Pharmaceuticals, Inc. |
Human interleukin-1 receptor antagonist—hybrid Fc fusion protein
|
EP2633317A1
(de)
|
2010-10-25 |
2013-09-04 |
Genentech, Inc. |
Behandlung von magen-darm-entzündung und psoriasis a
|
TWI619811B
(zh)
*
|
2010-11-08 |
2018-04-01 |
諾華公司 |
趨化細胞素受體結合多肽
|
JP6067575B2
(ja)
|
2010-12-17 |
2017-01-25 |
ニューリミューン ホールディング エイジー |
ヒト抗sod1抗体
|
KR101965461B1
(ko)
|
2011-05-20 |
2019-04-04 |
앨더바이오 홀딩스 엘엘씨 |
필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
|
SG194974A1
(en)
|
2011-05-20 |
2013-12-30 |
Alderbio Holdings Llc |
Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
|
EP2710039B1
(de)
|
2011-05-20 |
2019-01-09 |
AlderBio Holdings LLC |
Anti-cgrp-zusammensetzungen und ihre verwendung
|
MX347818B
(es)
|
2011-05-21 |
2017-05-15 |
Macrogenics Inc |
Dominios que enlazan suero desinmunizados y su uso para prolongar la vida media en suero.
|
MX347514B
(es)
|
2011-05-25 |
2017-04-28 |
Innate Pharma Sa |
Anticuerpos anti-receptores tipo inmunoglobulina citoliticos (kir) para el tratamiento de trastornos inflamatorios.
|
US9580493B2
(en)
|
2011-06-23 |
2017-02-28 |
Biogen International Neuroscience Gmbh |
Anti-α synuclein binding molecules
|
EP2723370A4
(de)
|
2011-06-24 |
2015-06-03 |
Univ Colorado Regents |
Zusammensetzungen, verfahren und verwendung für alpha-1-antitrypsin-fusionsmoleküle
|
CA2840944A1
(en)
*
|
2011-07-08 |
2013-01-17 |
Bayer Intellectual Property Gmbh |
Fusion proteins releasing relaxin and uses thereof
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
US20140234330A1
(en)
|
2011-07-22 |
2014-08-21 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
WO2013041722A1
(en)
*
|
2011-09-23 |
2013-03-28 |
Ablynx Nv |
Prolonged inhibition of interleukin-6 mediated signaling
|
US11951157B2
(en)
|
2011-10-11 |
2024-04-09 |
Universitat Zurich |
Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
|
AU2012322999B2
(en)
*
|
2011-10-11 |
2017-08-10 |
Universitat Zurich Prorektorat Mnw |
Combination medicament comprising IL-12 and an agent for blockade of T-cell inhibitory molecules for tumour therapy
|
BR112014009797A2
(pt)
|
2011-10-24 |
2020-10-27 |
Halozyme, Inc. |
diagnóstico de companhia para terapia de agente anti-hialuronano e métodos de uso do mesmo
|
WO2013106589A1
(en)
|
2012-01-10 |
2013-07-18 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
|
CA2865928C
(en)
|
2012-03-02 |
2021-02-16 |
Vaccinex, Inc. |
Cxcl13 antagonist for the treatment of sjogren's syndrome
|
WO2013172967A1
(en)
|
2012-05-17 |
2013-11-21 |
Extend Biosciences, Inc |
Carriers for improved drug delivery
|
DK2852610T3
(en)
|
2012-05-23 |
2018-09-03 |
Glykos Finland Oy |
PRODUCTION OF FUCOSYLED GLYCOPROTEIN
|
WO2013192504A1
(en)
|
2012-06-22 |
2013-12-27 |
The Trustees Of Dartmouth College |
Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
WO2014011775A1
(en)
|
2012-07-10 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Biomaterials for enhanced implant-host integration
|
ES2771324T3
(es)
|
2012-08-03 |
2020-07-06 |
Dana Farber Cancer Inst Inc |
Usos médicos de agentes que modulan la activación de las células inmunitarias y métodos de detección correspondientes
|
KR102134088B1
(ko)
|
2012-08-24 |
2020-07-14 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
|
JP6368308B2
(ja)
|
2012-09-07 |
2018-08-01 |
トラスティーズ・オブ・ダートマス・カレッジ |
癌の診断および治療のためのvista調節剤
|
US9278124B2
(en)
|
2012-10-16 |
2016-03-08 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
SI3575326T1
(sl)
|
2012-12-17 |
2022-08-31 |
Pf Argentum Ip Holdings Llc |
Zdravljenje bolnih celic CD47 s fuzijo SIRP ALFA FC
|
CA2896066C
(en)
|
2012-12-21 |
2022-07-12 |
Biogen Ma Inc. |
Human anti-tau antibodies
|
JP6407165B2
(ja)
|
2012-12-31 |
2018-10-17 |
ニューリミューン ホールディング エイジー |
ポリオーマウイルス関連疾患の治療および防止のための組換えヒト抗体
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
WO2014137355A1
(en)
|
2013-03-08 |
2014-09-12 |
Vaccinex, Inc. |
Anti-cxcl13 antibodies and associated epitope sequences
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
US9908938B2
(en)
|
2013-03-14 |
2018-03-06 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
|
CA2899089C
(en)
|
2013-03-15 |
2021-10-26 |
Biogen Ma Inc. |
Factor ix polypeptide formulations
|
SG10201808523RA
(en)
|
2013-03-15 |
2018-11-29 |
Genentech Inc |
Il-22 polypeptides and il-22 fc fusion proteins and methods of use
|
US9587235B2
(en)
|
2013-03-15 |
2017-03-07 |
Atyr Pharma, Inc. |
Histidyl-tRNA synthetase-Fc conjugates
|
PL2981822T3
(pl)
|
2013-05-06 |
2021-07-12 |
Scholar Rock, Inc. |
Kompozycje i sposoby modulacji czynnika wzrostu
|
AU2014275166B2
(en)
|
2013-06-06 |
2020-09-10 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment prevention, and treatment of cancer using PD-L1 isoforms
|
AR096891A1
(es)
|
2013-07-12 |
2016-02-03 |
Hanmi Pharm Ind Co Ltd |
Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
EP2839842A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
|
EP2840091A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
|
EP3757130A1
(de)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Verfahren zur behandlung von blutkrebs
|
WO2015085311A1
(en)
|
2013-12-07 |
2015-06-11 |
Case Western Reserve University |
Compositions and methods of treating thrombosis
|
WO2015095868A1
(en)
|
2013-12-20 |
2015-06-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
SI3712174T1
(sl)
|
2013-12-24 |
2022-06-30 |
Janssen Pharmaceutica Nv |
Protitelesa in delci proti VISTA
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
US10047133B2
(en)
*
|
2014-01-22 |
2018-08-14 |
Antagonis Biotherapeutics Gmbh |
Glycosaminoglycan-antagonising fusion proteins and methods of using same
|
US10556945B2
(en)
|
2014-03-21 |
2020-02-11 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
US9896502B2
(en)
|
2014-03-21 |
2018-02-20 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
KR102530900B1
(ko)
|
2014-03-31 |
2023-05-12 |
암젠 케이-에이, 인크. |
손발톱 및 두피 건선의 치료 방법
|
WO2015191881A2
(en)
|
2014-06-11 |
2015-12-17 |
Green Kathy A |
Use of vista agonists and antagonists to suppress or enhance humoral immunity
|
CA2953816C
(en)
|
2014-06-30 |
2022-03-15 |
Altor Bioscience Corporation |
Il-15-based molecules and methods of use thereof
|
CN108064266A
(zh)
|
2014-07-21 |
2018-05-22 |
格利科斯芬兰公司 |
在丝状真菌中具有哺乳动物样n-聚糖的糖蛋白的制备
|
EP3677285B1
(de)
|
2014-08-04 |
2023-12-13 |
Case Western Reserve University |
Gezielte peptide zur erkennung von prostatakrebs
|
US9616114B1
(en)
|
2014-09-18 |
2017-04-11 |
David Gordon Bermudes |
Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
|
SG11201702544WA
(en)
|
2014-09-29 |
2017-04-27 |
Univ Duke |
Bispecific molecules comprising an hiv-1 envelope targeting arm
|
KR20230104759A
(ko)
|
2014-09-30 |
2023-07-10 |
뉴리뮨 홀딩 아게 |
인간-유래의 항-디펩티드 반복체(dpr) 항체
|
WO2016062766A1
(en)
|
2014-10-21 |
2016-04-28 |
Ablynx Nv |
Treatment of il-6r related diseases
|
EP3220961B1
(de)
|
2014-10-22 |
2023-07-05 |
Extend Biosciences, Inc. |
Therapeutische vitamin-d-konjugate
|
WO2016065052A1
(en)
|
2014-10-22 |
2016-04-28 |
Extend Biosciences, Inc. |
Insulin vitamin d conjugates
|
US9789197B2
(en)
|
2014-10-22 |
2017-10-17 |
Extend Biosciences, Inc. |
RNAi vitamin D conjugates
|
AU2015357463B2
(en)
|
2014-12-05 |
2021-10-07 |
Immunext, Inc. |
Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
|
AU2015360903B2
(en)
|
2014-12-08 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
|
WO2016123329A2
(en)
|
2015-01-28 |
2016-08-04 |
Genentech, Inc. |
Gene expression markers and treatment of multiple sclerosis
|
US11820807B2
(en)
|
2015-06-12 |
2023-11-21 |
Ubi Pharma Inc |
Immunoglobulin fusion proteins and uses thereof
|
CA2990360C
(en)
|
2015-06-24 |
2024-02-13 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
JP6898303B2
(ja)
|
2015-08-07 |
2021-07-07 |
エーエルエックス オンコロジー インコーポレイテッド |
Sirp−アルファドメインまたはそのバリアントを有する構築物
|
CN108430506A
(zh)
|
2015-09-15 |
2018-08-21 |
得克萨斯州大学系统董事会 |
T细胞受体(tcr)结合抗体及其用途
|
US11338065B2
(en)
|
2015-10-08 |
2022-05-24 |
Massachusetts Institute Of Technology |
In situ expansion of engineered devices for regeneration
|
WO2017066561A2
(en)
|
2015-10-16 |
2017-04-20 |
President And Fellows Of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
EP3390364B1
(de)
|
2015-12-17 |
2020-07-15 |
Biokine Therapeutics Ltd. |
Kleine moleküle zur hemmung der chemokinaktivität und/oder des wachstums von krebzellen
|
WO2017103931A1
(en)
|
2015-12-17 |
2017-06-22 |
Biokine Therapeutics Ltd. |
Small molecules against cancer
|
EP3397274A1
(de)
|
2015-12-31 |
2018-11-07 |
The Regents of the University of Colorado, a body corporate |
Verfahren und verwendungen für alpha-1-antitrypsin oder rekombinante formen davon auf steroid-refraktärer graft-versus-host-krankheit mit gastrointestinalen komplikationen
|
JP2019509993A
(ja)
|
2016-02-12 |
2019-04-11 |
ヤンセン ファーマシューティカ エヌブイ |
抗vista(b7h5)抗体
|
KR102632796B1
(ko)
|
2016-03-10 |
2024-02-02 |
비엘라 바이오, 인크. |
Ilt7 결합 분자 및 이의 사용 방법
|
IL262396B2
(en)
|
2016-04-15 |
2023-09-01 |
Macrogenics Inc |
New b7-h3 binding molecules, drug-antibody conjugates and their uses
|
CA3020848A1
(en)
|
2016-04-15 |
2017-10-19 |
Janssen Pharmaceuticals, Inc. |
Anti-human vista antibodies and use thereof
|
KR20220148306A
(ko)
|
2016-05-27 |
2022-11-04 |
알토 바이오사이언스 코포레이션 |
Cd3 결합 도메인을 가지는 다량체 il-15 기반 분자의 구성 및 특성규명
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag |
新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用
|
JP6937368B2
(ja)
|
2016-09-23 |
2021-09-22 |
テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー |
難治性片頭痛の治療方法
|
SG11201903306SA
(en)
|
2016-10-21 |
2019-05-30 |
Altor Bioscience Corp |
Multimeric il-15-based molecules
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
JP2020506916A
(ja)
|
2017-01-30 |
2020-03-05 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性乾癬性関節炎の治療のための抗tnf抗体、組成物、及び方法
|
EP3579870A4
(de)
|
2017-02-07 |
2020-12-30 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Auf car-t-zell-tumor (ctct) abzielende phospholipidether (ple)-wirkstoffe
|
KR20190115042A
(ko)
|
2017-02-07 |
2019-10-10 |
얀센 바이오테크 인코포레이티드 |
활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
|
WO2018160540A1
(en)
|
2017-02-28 |
2018-09-07 |
Sanofi |
Therapeutic rna
|
CN110582288A
(zh)
|
2017-02-28 |
2019-12-17 |
恩多塞特公司 |
用于car t细胞疗法的组合物和方法
|
CN110785435B
(zh)
|
2017-03-06 |
2024-01-23 |
艾尔特生物科技公司 |
与il-12和il-18的基于il-15的融合物
|
US20190048055A1
(en)
|
2017-03-31 |
2019-02-14 |
Altor Bioscience Corporation |
Alt-803 in combination with anti-cd38 antibody for cancer therapies
|
AU2018256435A1
(en)
|
2017-04-20 |
2019-11-07 |
Atyr Pharma, Inc. |
Compositions and methods for treating lung inflammation
|
EP3618865A4
(de)
|
2017-05-05 |
2021-05-05 |
Vaccinex, Inc. |
Menschlicher anti-semaphorin-4d-antikörper
|
CA3074635A1
(en)
|
2017-08-28 |
2019-03-07 |
Altor Bioscience Llc |
Il-15-based fusions to il-7 and il-21
|
CN112292138A
(zh)
|
2018-01-22 |
2021-01-29 |
西雅图儿童医院(Dba西雅图儿童研究所) |
Car t细胞的使用方法
|
SG11202006259SA
(en)
|
2018-01-26 |
2020-08-28 |
Genentech Inc |
Il-22 fc fusion proteins and methods of use
|
HUE060435T2
(hu)
|
2018-01-26 |
2023-03-28 |
Hoffmann La Roche |
IL-22 Fc készítmények és alkalmazásukra szolgáló eljárások
|
JP2021514354A
(ja)
|
2018-02-21 |
2021-06-10 |
ジェネンテック, インコーポレイテッド |
IL−22Fc融合タンパク質による治療のための投与
|
EP3773657A4
(de)
|
2018-03-26 |
2021-12-08 |
Altor Bioscience LLC |
Anti-pdl1, il-15- und tgf-beta-rezeptor-kombinationsmoleküle
|
WO2019209078A1
(ko)
|
2018-04-26 |
2019-10-31 |
주식회사 굳티셀 |
신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
|
US20210196787A1
(en)
*
|
2018-06-28 |
2021-07-01 |
National University Corporation Okayama University |
Agent for enhancing phagocytosis ability of neutrophils
|
EP3827837A4
(de)
*
|
2018-07-24 |
2022-05-04 |
Good T Cells, Inc. |
Zusammensetzung zur vorbeugung oder behandlung von immunerkrankungen
|
CN110964116A
(zh)
|
2018-09-26 |
2020-04-07 |
北京辅仁瑞辉生物医药研究院有限公司 |
GLP1-Fc融合蛋白及其缀合物
|
KR20210113597A
(ko)
|
2019-01-08 |
2021-09-16 |
하. 룬드벡 아크티에셀스카브 |
항-cgrp 항체를 사용한 두통의 급성 치료 및 신속 치료
|
KR20210116540A
(ko)
|
2019-01-15 |
2021-09-27 |
얀센 바이오테크 인코포레이티드 |
소아 특발성 관절염의 치료를 위한 항-tnf 항체 조성물 및 방법
|
CN113330031A
(zh)
|
2019-01-23 |
2021-08-31 |
詹森生物科技公司 |
用于在治疗银屑病关节炎的方法中使用的抗tnf抗体组合物
|
US11028176B2
(en)
|
2019-02-13 |
2021-06-08 |
The Brigham And Women's Hospital, Inc. |
Anti-peripheral lymph node addressin antibodies and uses thereof
|
CA3133388A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
EP3938391A1
(de)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech, Inc. |
Verfahren zur herstellung von anti-tnf-antikörperzusammensetzungen
|
US20220153830A1
(en)
|
2019-03-14 |
2022-05-19 |
Janssen Biotech, Inc. |
Manufacturing Methods for Producing Anti-TNF Antibody Compositions
|
KR20220009442A
(ko)
|
2019-05-15 |
2022-01-24 |
아론바이오 리미티드 |
암 치료, 케모카인 활성 억제 및/또는 세포사 유도를 위한 소분자
|
EP3972690A4
(de)
|
2019-05-23 |
2023-07-05 |
Janssen Biotech, Inc. |
Verfahren zur behandlung einer entzündlichen darmerkrankung mit einer kombinationstherapie von antikörpern gegen il-23 und tnf-alpha
|
MA56045A
(fr)
|
2019-05-31 |
2022-04-06 |
Alx Oncology Inc |
Méthodes de traitement du cancer avec une protéine de fusion sirpalpha-fc en association avec un inhibiteur de point de contrôle immunitaire
|
EP3976648A1
(de)
|
2019-06-03 |
2022-04-06 |
Janssen Biotech, Inc. |
Anti-tnf-antikörperzusammensetzungen und verfahren zur behandlung von aktiver psoriasis-arthritis
|
AU2020288404A1
(en)
|
2019-06-03 |
2022-02-03 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
BR112022017718A2
(pt)
|
2020-03-05 |
2022-11-16 |
Diamedica Usa Inc |
Polipeptídeos de ulinastatina
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
WO2021230233A1
(ja)
*
|
2020-05-14 |
2021-11-18 |
学校法人日本医科大学 |
感染症の治療又は予防剤
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
AU2022306144A1
(en)
|
2021-07-09 |
2024-02-22 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
WO2023281463A1
(en)
|
2021-07-09 |
2023-01-12 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
WO2023168426A1
(en)
|
2022-03-03 |
2023-09-07 |
Enosi Therapeutics Corporation |
Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
|
WO2023173084A1
(en)
|
2022-03-11 |
2023-09-14 |
University Of Rochester |
Cyclopeptibodies and uses thereof
|
KR20230156844A
(ko)
|
2022-05-02 |
2023-11-14 |
노보 노르디스크 에이/에스 |
고농도 조성물 및 피하 투여에 적합한 신규한 항-angptl3 항체
|